• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Summit Therapeutics (SMMT)

Common Shares
Sell: $16.37|Buy: $16.42|Change: 0.88 (5.68%)

Open 

$18.91

Previous close 

$15.48

Trade high 

$19.09

Volume 

27,181,001

Year high 

$29.23

Year low 

$12.07

Dividend yield 

–

Market capitalisation 

$13.05 bn

P/E ratio 

26.36

ISIN 

US86627T1088

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Share price

Performance 28/09/2026

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann

Total return (%)
Summit Therapeutics- 0.83
More...

Company profile

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate isridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Sector 

Healthcare

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.